📊 OTLK Key Takeaways
Is Outlook Therapeutics, Inc. (OTLK) a Good Investment?
Outlook Therapeutics is a technically insolvent pre-revenue biotech company in critical financial distress: negative stockholders equity of -$38.5M, liabilities exceeding assets by $38.5M, severe liquidity crisis with 0.35x current ratio, and -$15.4M annual free cash burn against only $8.7M remaining cash, indicating potential insolvency within 6-12 months absent immediate capital infusion or revenue generation.
Why Buy Outlook Therapeutics, Inc. Stock? OTLK Key Strengths
- Maintains $8.7M in liquid cash providing near-term operational runway
- Long-term debt structure provides payment flexibility versus short-term obligations
- Pre-revenue biotech with potential clinical asset value if development programs advance
OTLK Stock Risks: Outlook Therapeutics, Inc. Investment Risks
- Technical insolvency: negative stockholders equity of -$38.5M with cumulative losses exceeding all assets
- Acute liquidity crisis: 0.35x current ratio indicates severe inability to meet short-term liabilities from current assets
- Unsustainable cash burn: -$15.4M free cash flow annually against $8.7M cash reserves = critical funding need within 6-12 months
- Zero revenue with -$13.5M operating losses and no demonstrated path to profitability
- High leverage: $35.6M debt against $18.2M total assets and negative equity
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Clinical development milestones and regulatory progress
- Capital raise announcements, debt restructuring, or acquisition/merger activity
Outlook Therapeutics, Inc. (OTLK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
OTLK Profit Margin, ROE & Profitability Analysis
OTLK vs Healthcare Sector: How Outlook Therapeutics, Inc. Compares
How Outlook Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Outlook Therapeutics, Inc. Stock Overvalued? OTLK Valuation Analysis 2026
Based on fundamental analysis, Outlook Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Outlook Therapeutics, Inc. Balance Sheet: OTLK Debt, Cash & Liquidity
OTLK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Outlook Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.06 indicates the company is currently unprofitable.
OTLK Revenue Growth, EPS Growth & YoY Performance
OTLK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.5M | -$11.2M | $-0.55 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Outlook Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
OTLK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Outlook Therapeutics, Inc. (CIK: 0001649989)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OTLK
What is the AI rating for OTLK?
Outlook Therapeutics, Inc. (OTLK) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OTLK's key strengths?
Claude: Maintains $8.7M in liquid cash providing near-term operational runway. Long-term debt structure provides payment flexibility versus short-term obligations.
What are the risks of investing in OTLK?
Claude: Technical insolvency: negative stockholders equity of -$38.5M with cumulative losses exceeding all assets. Acute liquidity crisis: 0.35x current ratio indicates severe inability to meet short-term liabilities from current assets.
What is OTLK's revenue and growth?
Outlook Therapeutics, Inc. reported revenue of $0.0.
Does OTLK pay dividends?
Outlook Therapeutics, Inc. does not currently pay dividends.
Where can I find OTLK SEC filings?
Official SEC filings for Outlook Therapeutics, Inc. (CIK: 0001649989) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OTLK's EPS?
Outlook Therapeutics, Inc. has a diluted EPS of $-0.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OTLK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Outlook Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OTLK stock overvalued or undervalued?
Valuation metrics for OTLK: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OTLK stock in 2026?
Our dual AI analysis gives Outlook Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OTLK's free cash flow?
Outlook Therapeutics, Inc.'s operating cash flow is $-14.9M, with capital expenditures of $437.3K.
How does OTLK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.35 (avg: 2).